07 maj: Alm. Brand A/S - Ugentlig rapportering om aktietilbagekøb
07 maj: Konsolidators udbud overtegnet med 141%
07-05-2019 13:00:00

Zealand Pharma enrolls first patient in Phase 3 extension study of glepaglutide for treatment for short bowel syndrome

Press release – No. 10 / 2019

Zealand Pharma enrolls first patient in Phase 3 extension study of glepaglutide for treatment for short bowel syndrome

  • The Phase 3 extension trial will evaluate long-term safety and efficacy of glepaglutide and enrolls short bowel syndrome (SBS) patients that have completed the pivotal Phase 3 trial.

     

  • The pivotal Phase 3 registration trial with glepaglutide for the treatment of SBS remains on track with results expected in 2020.

     

  • Glepaglutide is a long-acting GLP-2 analog with potential for once-weekly dosing in an auto-injector pen.

Copenhagen, May 7, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has enrolled the first patient in a Phase 3 extension trial to evaluate the long-term safety and efficacy of glepaglutide treatment in patients with short bowel syndrome (SBS).

Patients who have completed either of the preceding Phase 2 and Phase 3 trials for glepaglutide as treatment for SBS may be eligible to participate in the Phase 3 extension trial. Safety and efficacy will be evaluated throughout a two-year duration.

“We are focused on improving the lives of people living with short bowel syndrome, and this extended trial demonstrates our commitment to delivering better treatment options for SBS,” said Emmanuel Dulac, President and Chief Executive Officer at Zealand Pharma. “We are grateful for the SBS patients that participate in our clinical studies. It’s our intention that this extension trial will help patients continue their pursuit of better health outcomes by improving intestinal absorption with glepaglutide.”

“Transitioning SBS patients into the glepaglutide extension trial is a positive advancement. We interpret it as a sign of good study conduct as well as good tolerability of the product,” added Adam Steensberg, Executive Vice President and Chief Medical and Development Officer at Zealand Pharma.

Additional details about the Phase 3 extension trial of glepaglutide to treat SBS can be found on ClinicalTrials.gov.

For further information, please contact:

Emmanuel Dulac, President and Chief Executive Officer

Tel.: +45 50 60 36 36, e-mail: edu@zealandpharma.com

Lani Pollworth Morvan, Investor Relations and Communication

Tel.: +45 50 60 37 78, e-mail: lpm@zealandpharma.com

About short bowel syndrome (SBS)

SBS is a complex chronic and severe condition associated with reduced or complete loss of intestinal function. Many patients have to be connected to infusion lines and pumps every day, which pose significant restrictions on their ability to engage in daily activities. In addition, they are at risk of experiencing a number of serious and life-threatening complications such as sepsis, blood clots, liver damage and renal impairment.

About glepaglutide

Glepagtluide is a long-acting GLP-2 analog being developed in an auto-injector with potential for convenient weekly administration as treatment for short bowel syndrome (SBS). Zealand Pharma aspires to provide the next generation, best-in-class therapies to help transform the lives of people living with SBS. Glepaglutide has the potential to be a best-in-class GLP-2 therapy, allowing people with SBS a fast, reliable and well-tolerated treatment option to reduce dependence on parenteral support.

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.  

 

Attachment

Z_ID_ORG_FINAL_w_name_rgb_NEW2.jpg

Relateret indhold
22 aug - 
Zealand Pharma/Nordea: Hæver kursmål til 187 kr. og gen..
19 aug - 
Mandagens aktier: Plusser i Drilling og Mærsk holdt C25..
19 aug - 
Aktier/middag: Novo og andre defensive trækker C25 i mi..
Relateret debat
22 aug - 
"Videre nedgang til 133 eller lavere er signaleret" ifl..
22 aug - 
Tak!
22 aug - 
Den skal lige have et eftertrykkeligt tryk 16 før vi fo..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
22 aug
ZEAL
Her er hvad Nordea skriver: We remove a USD 25m estimated upfront payment from a partner deal on the..
4
22 aug
ZEAL
ZEALAND PHARMA/NORDEA: HÆVER KURSMÅL TIL 187 KR. OG GENTAGER KØB 07:45Nordea hæver kursmålet for akt..
4
20 aug
ZEAL
Ja, og denn røg ud af diverse TA-trendlinier og blev spået nedad...(det kan selvfølgelig nåes endnu)..
3
20 aug
ZEAL
Sjovt som man kan tage fejl .. igår anbefalede man at tage gevinst hjem på denne side under nyheder ..
3
17 aug
ZEAL
Du har helt ret alt skal tages i betragtning også de negative kursmål.Her er konsensus pt.:https://w..
3
22 aug
ZEAL
Den skal lige have et eftertrykkeligt tryk 16 før vi forsætter opad!
2
17 aug
ZEAL
Tror på 300-350 som kursmål fra fx DB inden 12 mdr.
2
20 aug
ZEAL
Er hypoglykæmi ikke ved at være på tilbagetog, pga. bedre diabetes medicin år for år?   Hypopal er v..
1
17 aug
ZEAL
Jeg aner ikke en dyt om, hvor aktien skal hen, alt afhænger af Deres produkter, går alt efter bogen..
1
17 aug
ZEAL
Det et noget et spring, yderlighederne bund i 92 top i 185 ;)   Sådan en gardering kan jeg nok også ..
1

Vestas' største kinesiske konkurrent oplever dyk i overskuddet

23-08-2019 15:14:38
Den kinesiske vindmølleproducent Goldwind, som er verdens næststørste af sin slags efter Vestas, måtte i første halvår se sit overskud skrumpe med 22,6 pct. til 1,18 mia. yuan.Omsætningen for perioden er opgjort til 15,73 mia. yuan, fremgår det af Bloomberg News.Goldwind havde i 2018 en markedsandel globalt på 14,7 pct. - og var dermed nummer to efter Vestas med en andel på 22,2 pct.Nummer tre var..

Kina gengælder amerikansk told: Aktiefutures falder

Relaterede nyheder
23-08-2019 14:27:22
Kina vil indføre told på 5-10 pct. på amerikanske varer for yderligere 75 mia. dollar som en gengældelse af amerikanernes told på varer, som importeres fra Kina.Tolden indføres i to etaper henholdsvis 1. september og 1. december.Det skriver Bloomberg News.Ifølge det kinesiske medie Xinhua varsler Kina også en told på 25 pct. på amerikanske biler fra 15. december, og sojaimporten fra USA pålægges e..

Sydbank sænker Ambu-anbefaling - flere finanshuse retter kursmål efter nedjustering

23-08-2019 11:27:06
Sydbank ser en aktie i Ambu som "mindre attraktiv" end tidligere, efter medicoselskabet senest i denne uge skar i forventningerne til resultaterne for hele 2018/19.Derfor sættes anbefalingen ned til "hold" fra "køb", skriver Søren Løntoft Hansen, senioraktieanalytiker i Sydbank.- I kølvandet på strategiopdateringen i juni og gårsdagens melding om investeringerne i det direkte salg i USA har vi sæn..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Ambu/SEB: Sænker kursmål og gentager anbefaling
2
KORR: Trump efter Powells tale: Hvem er den største fjende? - NY
3
Kina gengælder amerikansk told: Aktiefutures falder
4
Sydbank sænker Ambu-anbefaling - flere finanshuse retter kursmål efter nedjustering
5
Aktier/åbning: Rockwool drøner ned i grønt marked

Relaterede aktiekurser

Zealand Pharma A/S 140,00 1,3% Stigning i aktiekurs
Zealand Pharma Aktiesels.. 140,00 1,3% Stigning i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. august 2019 07:03:33
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190819.1 - EUROWEB3 - 2019-08-24 07:03:33 - 2019-08-24 07:03:33 - 1 - Website: OKAY